The role of adjuvant platinum‐based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery

J. Saunders(Nottingham University Hospitals NHS Trust), Simon L. Parsons(Galapagos (Belgium)), E Umer Mumtaz(Nottingham University Hospitals NHS Trust), Philip Kaye(Nottingham University Hospitals NHS Trust), Irshad Soomro, C R Bowman(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Matthew S. Dorrington(University of Nottingham), Alexander M. Reece-Smith(Nottingham University Hospitals NHS Trust)
Journal of Surgical Oncology
March 2, 2017
10.1002/jso.24601
Cited by 39

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
|Gastroenterology|2012|378
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374